CARYN CHASANOV: Open Payments
NPI 1992021687 · LEWES, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,739 in 130 payments from 36 companies in 2025. Trend: 2023 $2,906 · 2024 $2,534 · 2025 $3,739
Food & beverage: $3,539Education: $200
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $783 |
| Actelion Pharmaceuticals US, Inc. | 8 | $295 |
| GENZYME CORPORATION | 12 | $231 |
| HARMONY BIOSCIENCES LLC | 6 | $228 |
| Merck Sharp & Dohme LLC | 4 | $203 |
| Novo Nordisk Inc | 7 | $181 |
| GlaxoSmithKline, LLC. | 10 | $154 |
| Axsome Therapeutics, Inc. | 2 | $149 |
| SANOFI-AVENTIS U.S. LLC | 2 | $124 |
| Verona Pharma, Inc. | 6 | $111 |
Products named: DUPIXENT, FASENRA, WAKIX, OPSUMIT, WINREVAIR, BREZTRI, TEZSPIRE, Sunosi.
Industry payments across DE — which companies pay providers there.
